ADPKD Gene Therapy Development at Newly Launched Estuary Biotherapeutics

Estuary Biotherapeutics emerges with $103M for kidney disease drugs

ADPKD Gene Therapy Development at Newly Launched Estuary Biotherapeutics

Estuary has established a team of scientists and advisors with expertise across genetic medicine, kidney biology, and drug development to continue research into therapies that can translate to human patients.

Biogen-backed Estuary nabs $93M for kidney disease gene therapy

The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."

Estuary Biotherapeutics Launches with $103M to Advance Gene Therapies for Kidney Disease

Estuary Biotherapeutics, Inc., a biotechnology company developing targeted genetic medicines for serious kidney diseases, has launched with $103 million in... The post Estuary Biotherapeutics Launches with $103M to Advance Gene Therapies for Kidney Disease appeared first on citybiz.

Estuary debuts with $103M to develop kidney disease gene therapies

Estuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type of inherited kidney disease. The company’s cash comes from a ...

Estuary Biotherapeutics launches with $103 million to advance targeted gene therapies for kidney disease

4BIO Ventures III has participated in the USD 93M Series A financing of Estuary Biotherapeutics (Estuary), following its co-lead of the company’s USD 10M Seed round with GV.